-
公开(公告)号：US10316018B2
公开(公告)日：2019-06-11
申请号：US16206166
申请日：2018-11-30
Applicant: PFIZER INC.
Inventor： Katherine Lin Lee , Christophe Philippe Allais , Christoph Martin Dehnhardt , Lori Krim Gavrin , Seungil Han , David Hepworth , Arthur Lee , Frank Eldridge Lovering , John Paul Mathias , Dafydd Rhys Owen , Nikolaos Papaioannou , Eddine Saiah , Joseph Walter Strohbach , John David Trzupek , Stephen Wayne Wright , Christoph Wolfgang Zapf
IPC: A61K31/4375 , A61K31/4709 , A61K31/4725 , A61K31/4745 , A61K31/4015 , A61K45/06 , C07D401/12 , C07D413/04 , C07D207/273 , C07D491/18 , C07D471/04 , C07D413/14 , C07D401/14
Abstract: Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula Ia, as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.
-
公开(公告)号：US10174000B2
公开(公告)日：2019-01-08
申请号：US15754650
申请日：2016-08-16
Applicant: PFIZER INC.
Inventor： Katherine Lin Lee , Christophe Philippe Allais , Christoph Martin Dehnhardt , Lori Krim Gavrin , Seungil Han , David Hepworth , Arthur Lee , Frank Eldridge Lovering , John Paul Mathias , Dafydd Rhys Owen , Nikolaos Papaioannou , Eddine Saiah , Joseph Walter Strohbach , John David Trzupek , Stephen Wayne Wright , Christoph Wolfgang Zapf
IPC: C07D207/273 , C07D401/12 , C07D401/14 , C07D413/04 , C07D413/14 , C07D471/04 , C07D491/18 , A61K31/4015 , A61K31/4375 , A61K31/4709 , A61K31/4725 , A61K31/4745 , A61K45/06
Abstract: Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula Ia, as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.
-
公开(公告)号：US20170233371A1
公开(公告)日：2017-08-17
申请号：US15497862
申请日：2017-04-26
Applicant: Pfizer Inc.
Inventor： Mark Edward Schnute , Gõran Mattias Wennerstål , James Robert Blinn , Neelu Kaila , James Richard Kiefer, Jr. , Scot Richard Mente , Ravi G. Kurumbail , Marvin Jay Meyers , Atli Thorarensen , Li Xing , Christoph Wolfgang Zapf , Edouard Zamaratski , Andrew Christopher Flick , Peter Jones
IPC: C07D401/14 , C07D413/14 , C07D405/14 , C07D413/04 , C07D471/04 , C07D487/04 , C07D403/04 , C07D401/04 , C07D417/14
CPC classification number: C07D401/14 , A61K31/454 , A61K31/497 , A61K31/506 , A61K31/519 , A61K31/5355 , C07D401/04 , C07D403/04 , C07D405/14 , C07D407/14 , C07D413/04 , C07D413/14 , C07D417/14 , C07D471/04 , C07D487/04 , Y02A50/406 , A61K2300/00
Abstract: The present invention provides compounds, pharmaceutical compositions, methods of inhibiting RORγ activity and/or reducing the amount of IL-17 in a subject, and methods of treating various medical disorders using such compounds and pharmaceutical compositions.
-
公开(公告)号：US20160046597A1
公开(公告)日：2016-02-18
申请号：US14448220
申请日：2014-07-31
Applicant: PFIZER INC.
Inventor： Mark Edward Schnute , Göran Mattias Wennerstål , James Robert Blinn , Neelu Kaila , James Richard Kiefer, JR. , Scot Richard Mente , Ravi G. Kurumbail , Marvin Jay Meyers , Atli Thorarensen , Li Xing , Christoph Wolfgang Zapf , Edouard Zamaratski , Andrew Christopher Flick , Peter Jones
IPC: C07D401/04 , C07D413/14 , C07D403/04 , C07D417/14 , C07D471/04 , C07D487/04 , C07D401/14 , C07D405/14
CPC classification number: C07D401/14 , A61K31/454 , A61K31/497 , A61K31/506 , A61K31/519 , A61K31/5355 , C07D401/04 , C07D403/04 , C07D405/14 , C07D407/14 , C07D413/04 , C07D413/14 , C07D417/14 , C07D471/04 , C07D487/04 , Y02A50/406 , A61K2300/00
Abstract: The present invention provides compounds, pharmaceutical compositions, methods of inhibiting RORγ activity and/or reducing the amount of IL-17 in a subject, and methods of treating various medical disorders using such compounds and pharmaceutical compositions.
Abstract translation: 本发明提供化合物，药物组合物，抑制受试者的RORγ活性和/或减少IL-17的量的方法，以及使用这些化合物和药物组合物治疗各种医学病症的方法。
-
公开(公告)号：US20150284405A1
公开(公告)日：2015-10-08
申请号：US14678114
申请日：2015-04-03
Applicant: Pfizer Inc.
Inventor： John David Trzupek , Katherine Lin Lee , Mark Edward Bunnage , Seungil Han , David Hepworth , Frank Eldridge Lovering , John Paul Mathias , Nikolaos Papaioannou , Betsy Susan Pierce , Joseph Walter Strohbach , Stephen Wayne Wright , Christoph Wolfgang Zapf , Lori Krim Gavrin , Arthur Lee , David Randolph Anderson , Kevin Joseph Curran , Christoph Martin Dehnhardt , Eddine Saiah , Joel Adam Goldberg , Xiaolun Wang , Horng-Chih Huang , Richard Vargas , Michael Dennis Lowe , Akshay Patny
IPC: C07D491/056 , A61K31/4709 , A61K45/06 , C07D405/12 , C07D215/48 , A61K31/47 , A61K31/4725 , C07D417/12 , A61K31/541 , C07D413/12 , A61K31/5377 , C07D207/26 , A61K31/4015 , C07D407/14 , C07D487/04 , C07D403/12 , A61K31/517 , C07D401/12
CPC classification number: C07D491/056 , A61K31/40 , A61K31/4015 , A61K31/47 , A61K31/4709 , A61K31/4725 , A61K31/517 , A61K31/5377 , A61K31/541 , A61K45/06 , C07C69/94 , C07D207/08 , C07D207/26 , C07D207/267 , C07D207/273 , C07D209/52 , C07D215/48 , C07D217/02 , C07D217/22 , C07D217/24 , C07D239/86 , C07D239/88 , C07D263/24 , C07D401/12 , C07D401/14 , C07D403/12 , C07D405/12 , C07D405/14 , C07D407/14 , C07D413/12 , C07D417/12 , C07D487/04 , C07D498/04 , C07F7/1804
Abstract: Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula Ia, as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.
Abstract translation: 公开了化合物的化合物，互变异构体和药学上可接受的盐，其中化合物具有如说明书中定义的式Ia结构。 还公开了相应的药物组合物，治疗方法，合成方法和中间体。
-
Patent Agency Ranking
公开(公告)号：US12202836B2
公开(公告)日：2025-01-21
申请号：US18342977
申请日：2023-06-28
Applicant: Pfizer Inc.
Inventor： John David Trzupek , Katherine Lin Lee , Mark Edward Bunnage , Seungil Han , David Hepworth , Frank Eldridge Lovering , John Paul Mathias , Nikolaos Papaioannou , Betsy Susan Pierce , Joseph Walter Strohbach , Stephen Wayne Wright , Christoph Wolfgang Zapf , Lori Krim Gavrin , Arthur Lee , David Randolph Anderson , Kevin Joseph Curran , Christoph Martin Dehnhardt , Eddine Saiah , Joel Adam Goldberg , Xiaolun Wang , Horng-Chih Huang , Richard Vargas , Michael Dennis Lowe , Akshay Patny
IPC: C07D491/056 , A61K31/40 , A61K31/4015 , A61K31/47 , A61K31/4709 , A61K31/4725 , A61K31/517 , A61K31/5377 , A61K31/541 , A61K45/06 , C07C69/94 , C07D207/08 , C07D207/26 , C07D207/267 , C07D207/273 , C07D209/52 , C07D215/48 , C07D217/02 , C07D217/22 , C07D217/24 , C07D239/86 , C07D239/88 , C07D263/24 , C07D401/12 , C07D401/14 , C07D403/12 , C07D405/12 , C07D405/14 , C07D407/14 , C07D413/12 , C07D417/12 , C07D487/04 , C07D498/04 , C07F7/18
Abstract: Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula Ia, as defined in the specification. In an embodiment, a pharmaceutical composition can be in a liquid dosage form and can comprise a therapeutically effective amount of the compound or a pharmaceutically acceptable salt thereof as an adjuvant and a therapeutic agent. In another embodiment, a method of adjuvant treating a disorder or condition can comprising administering the pharmaceutical composition to a patient.
-
公开(公告)号：US11702424B2
公开(公告)日：2023-07-18
申请号：US16996117
申请日：2020-08-18
Applicant: Pfizer Inc.
Inventor： John David Trzupek , Katherine Lin Lee , Mark Edward Bunnage , Seungil Han , David Hepworth , Frank Eldridge Lovering , John Paul Mathias , Nikolaos Papaioannou , Betsy Susan Pierce , Joseph Walter Strohbach , Stephen Wayne Wright , Christoph Wolfgang Zapf , Lori Krim Gavrin , Arthur Lee , David Randolph Anderson , Kevin Joseph Curran , Christoph Martin Dehnhardt , Eddine Saiah , Joel Adam Goldberg , Xiaolun Wang , Horng-Chih Huang , Richard Vargas , Michael Dennis Lowe , Akshay Patny
IPC: C07D491/056 , C07F7/18 , C07D401/14 , C07D405/14 , C07D217/02 , C07D217/22 , C07D217/24 , C07D239/86 , C07D239/88 , C07D263/24 , C07D207/273 , C07D498/04 , C07D209/52 , A61K31/4015 , A61K31/47 , A61K31/4709 , A61K31/4725 , A61K31/517 , A61K31/5377 , C07C69/94 , A61K31/541 , A61K45/06 , C07D207/26 , C07D215/48 , C07D401/12 , C07D403/12 , C07D405/12 , C07D407/14 , C07D413/12 , C07D417/12 , C07D487/04 , A61K31/40 , C07D207/08 , C07D207/267
CPC classification number: C07D491/056 , A61K31/40 , A61K31/4015 , A61K31/47 , A61K31/4709 , A61K31/4725 , A61K31/517 , A61K31/5377 , A61K31/541 , A61K45/06 , C07C69/94 , C07D207/08 , C07D207/26 , C07D207/267 , C07D207/273 , C07D209/52 , C07D215/48 , C07D217/02 , C07D217/22 , C07D217/24 , C07D239/86 , C07D239/88 , C07D263/24 , C07D401/12 , C07D401/14 , C07D403/12 , C07D405/12 , C07D405/14 , C07D407/14 , C07D413/12 , C07D417/12 , C07D487/04 , C07D498/04 , C07F7/1804
Abstract: Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula Ia,
as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.-
公开(公告)号：US20210002251A1
公开(公告)日：2021-01-07
申请号：US17025026
申请日：2020-09-18
Applicant: Pfizer Inc.
Inventor： John Robert Springer , Balekudru Devadas , Danny James Garland , Margaret Lanahan Grapperhaus , Seungil Han , Susan Landis Hockerman , Robert Owen Hughes , Eddine Saiah , Mark Edward Schnute , Shaun Raj Selness , Daniel Patrick Walker , Zhao-Kui Wan , Li Xing , Christoph Wolfgang Zapf , Michelle Ann Schmidt
IPC: C07D401/04
Abstract: Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (BTK). Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the BTK inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions. (Formula I)
-
公开(公告)号：US20200377511A1
公开(公告)日：2020-12-03
申请号：US16996117
申请日：2020-08-18
Applicant: Pfizer Inc.
Inventor： John David Trzupek , Katherine Lin Lee , Mark Edward Bunnage , Seungil Han , David Hepworth , Frank Eldridge Lovering , John Paul Mathias , Nikolaos Papaioannou , Betsy Susan Pierce , Joseph Walter Strohbach , Stephen Wayne Wright , Christoph Wolfgang Zapf , Lori Krim Gavrin , Arthur Lee , David Randolph Anderson , Kevin Joseph Curran , Christoph Martin Dehnhardt , Eddine Saiah , Joel Adam Goldberg , Xiaolun Wang , Horng-Chih Huang , Richard Vargas , Michael Dennis Lowe , Akshay Patny
IPC: C07D491/056 , C07F7/18 , C07D401/14 , C07D405/14 , C07D217/02 , C07D217/22 , C07D217/24 , C07C69/94 , C07D239/86 , C07D239/88 , C07D263/24 , C07D207/273 , C07D498/04 , C07D209/52 , A61K31/4015 , A61K31/47 , A61K31/4709 , A61K31/4725 , A61K31/517 , A61K31/5377 , A61K31/541 , A61K45/06 , C07D207/26 , C07D215/48 , C07D401/12 , C07D403/12 , C07D405/12 , C07D407/14 , C07D413/12 , C07D417/12 , C07D487/04 , A61K31/40 , C07D207/08 , C07D207/267
Abstract: Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula Ia, as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.
-
公开(公告)号：US20200039960A1
公开(公告)日：2020-02-06
申请号：US16656702
申请日：2019-10-18
Applicant: Pfizer Inc.
Inventor： Mark Edward Schnute , Göran Mattias Wennerstål , James Robert Blinn , Neelu Kaila , James Richard Kiefer, Jr. , Scot Richard Mente , Ravi G. Kurumbail , Marvin Jay Meyers , Atli Thorarensen , Li Xing , Christoph Wolfgang Zapf , Edouard Zamaratski , Andrew Christopher Flick , Peter Jones
IPC: C07D401/14 , C07D413/14 , A61K31/454 , A61K31/497 , A61K31/506 , A61K31/519 , A61K31/5355 , C07D407/14 , C07D413/04 , C07D417/14 , C07D471/04 , C07D487/04 , C07D401/04 , C07D403/04 , C07D405/14
Abstract: The present invention provides compounds, pharmaceutical compositions, methods of inhibiting RORγ activity and/or reducing the amount of IL-17 in a subject, and methods of treating various medical disorders using such compounds and pharmaceutical compositions.
-
-
-
-
-
-
-
-
-
Search Results
25
records
(took 0.066 seconds)
